Literature DB >> 27531005

Mid-to-long-term follow-up results of transcatheter closure of atrial septal defect in patients older than 40 years.

Jou-Kou Wang1, Shuenn-Nan Chiu2, Ming-Tai Lin2, Chun-An Chen2, Chun-Wei Lu2, Mei-Hwan Wu2.   

Abstract

We investigated the mid-to-long-term results of transcatheter closure of atrial septal defect (ASD) in patients ≥40 years since there are issues with patients presenting with pulmonary hypertension and arrhythmia at the time of closure. In an 8.8 year period, transcatheter closure of ASD was successful in 179 patients aged ≥40 years, but failed in 2. Of the 179 patients (44 males, median 53 years), NYHA functional class, presence of arrhythmia and severity of pulmonary hypertension were compared before and after closure. Patients with pulmonary hypertension (n = 43, 24 %) were significantly older (60 ± 11 vs. 52 ± 9 years, p < 0.01) and required larger devices (27 ± 7 vs. 24 ± 7 mm, p = 0.04) than those without. Arrhythmia before intervention was documented in 31 patients (17.3 %): 22 atrial fibrillation (AF), 4 atrial flutter and 5 supraventricular tachycardia. Patients with AF or atrial flutter (n = 26) were significantly older (63 ± 10 vs. 53 ± 10 years, p = 0.048) and had a higher pulmonary artery mean pressure (29.2 ± 12.6 vs. 20.2 ± 7.6 mmHg, p = 0.041) than those without. The mean follow-up period was 3.8 ± 2.1 years. Early new-onset arrhythmia was documented in 23 patients of whom 1 had persistent AF, 1 developed sick sinus syndrome and others were in sinus rhythm at latest visit. There was significant improvement in NYHA functional class after closure (p < 0.001). Of the 22 patients with AF, 10 were in sinus rhythm, 1 had paroxysmal AF, and 11 had persistent AF. Pulmonary hypertension persisted in 13 patients. Transcatheter closure of atrial septal defect in patients above 40 years is beneficial in terms of NYHA functional class, pulmonary artery pressure and cardiac rhythm.

Entities:  

Keywords:  Age above forty; Atrial fibrillation; Atrial septal defect; Pulmonary hypertension; Transcatheter closure

Mesh:

Year:  2016        PMID: 27531005     DOI: 10.1007/s00380-016-0886-y

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  40 in total

Review 1.  Atrial septal defects in the adult: recent progress and overview.

Authors:  Gary Webb; Michael A Gatzoulis
Journal:  Circulation       Date:  2006-10-10       Impact factor: 29.690

2.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.

Authors:  B J Kircher; R B Himelman; N B Schiller
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

3.  Incidence of atrial fibrillation following transcatheter closure of atrial septal defects in adults.

Authors:  Christian Spies; Abha Khandelwal; Ines Timmermanns; Rainer Schräder
Journal:  Am J Cardiol       Date:  2008-07-17       Impact factor: 2.778

4.  Benefit of atrial septal defect closure in adults: impact of age.

Authors:  Michael Humenberger; Raphael Rosenhek; Harald Gabriel; Florian Rader; Maria Heger; Ursula Klaar; Thomas Binder; Peter Probst; Georg Heinze; Gerald Maurer; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2010-10-12       Impact factor: 29.983

5.  Do patients over 40 years of age benefit from surgical closure of atrial septal defects?

Authors:  M Jemielity; W Dyszkiewicz; L Paluszkiewicz; B Perek; P Buczkowski; A Ponizyński
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

6.  Fate of preoperative atrial fibrillation after correction of atrial septal defect.

Authors:  Jin Wi; Jae-Young Choi; Jae-Min Shim; Jae-Sun Uhm; Hye-Jin Hwang; Jong-Youn Kim; Hui-Nam Pak; Boyoung Joung; Moonhyoung Lee
Journal:  Circ J       Date:  2012-10-16       Impact factor: 2.993

7.  Improvement in exercise capacity in asymptomatic and mildly symptomatic adults after atrial septal defect percutaneous closure.

Authors:  Marie-Claude Brochu; Jean-François Baril; Annie Dore; Martin Juneau; Pierre De Guise; Lise-Andrée Mercier
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

8.  Repaired and open atrial septal defects type II in adulthood: an epidemiological study of a large European cohort.

Authors:  Peter Engelfriet; Folkert Meijboom; Eric Boersma; Jan Tijssen; Barbara Mulder
Journal:  Int J Cardiol       Date:  2007-06-22       Impact factor: 4.164

9.  Closure of atrial septal defect with the Amplatzer septal occluder in adults.

Authors:  Nicolas Majunke; Jacek Bialkowski; Neil Wilson; Malgorzata Szkutnik; Jacek Kusa; Andreas Baranowski; Corinna Heinisch; Stefan Ostermayer; Nina Wunderlich; Horst Sievert
Journal:  Am J Cardiol       Date:  2008-12-25       Impact factor: 2.778

Review 10.  Atrial septal defect closure is associated with a reduced prevalence of atrial tachyarrhythmia in the short to medium term: a systematic review and meta-analysis.

Authors:  Joshua A Vecht; Srdjan Saso; Christopher Rao; Konstantinos Dimopoulos; Julia Grapsa; Cesare M Terracciano; Nicholas S Peters; Petros Nihoyannopoulos; Elaine Holmes; Michael A Gatzoulis; Thanos Athanasiou
Journal:  Heart       Date:  2010-11       Impact factor: 5.994

View more
  3 in total

1.  Persistence of an iatrogenic atrial septal defect after a second-generation cryoballoon ablation of atrial fibrillation.

Authors:  Tomonori Watanabe; Shinsuke Miyazaki; Takatsugu Kajiyama; Sadamitsu Ichijo; Takamitsu Takagi; Miyako Igarashi; Hiroaki Nakamura; Hiroshi Taniguchi; Hitoshi Hachiya; Yoshito Iesaka
Journal:  Heart Vessels       Date:  2018-03-17       Impact factor: 2.037

Review 2.  General Concepts in Adult Congenital Heart Disease.

Authors:  Ferit Onur Mutluer; Alpay Çeliker
Journal:  Balkan Med J       Date:  2018-01-20       Impact factor: 2.021

3.  Percutaneous Atrial Septal Defect Closure Using the Occlutech Figulla Device in Adults: More than 800 Patient-Years of Follow-Up.

Authors:  R J R Snijder; L E Renes; D Bosshardt; M J Suttorp; J M Ten Berg; M C Post
Journal:  J Interv Cardiol       Date:  2020-02-14       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.